Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron‐Chelating Agent in Patients with Transfusion‐Dependent Iron Overload Due to β‐Thalassemia
- 1 June 2003
- journal article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 43 (6), 565-572
- https://doi.org/10.1177/0091270003253350
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detectionJournal of Chromatography B: Biomedical Sciences and Applications, 2001
- The Thalassaemia SyndromesPublished by Wiley ,2001
- DeferiproneDrugs, 1999
- Iron-Chelating Therapy and the Treatment of ThalassemiaBlood, 1997
- Iron Excretion in Thalassaemia Major After Administration of Chelating AgentsBMJ, 1962